BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25535899)

  • 1. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
    Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 6. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
    Lou YF; Zou ZZ; Chen PJ; Huang GB; Li B; Zheng DQ; Yu XR; Luo XY
    PLoS One; 2014; 9(5):e97719. PubMed ID: 24874286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
    Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Feng YH; Tsao CJ; Wu CL; Chang JG; Lu PJ; Yeh KT; Shieh GS; Shiau AL; Lee JC
    Cancer Sci; 2010 Sep; 101(9):2033-8. PubMed ID: 20624167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
    Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
    Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
    Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
    ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
    Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
    Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
    Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.